Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis

<p><strong>Introduction: </strong>Pain is a multidimensional factor and core domain of psoriatic arthritis (PsA). This analysis aimed to quantify the role of potential inflammation-associated outcomes on pain reduction in patients with PsA receiving tofacitinib, using medi...

Bibliografski detalji
Glavni autori:	de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC
Format:	Journal article
Jezik:	English
Izdano:	Springer 2022

Slični predmeti

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
od: de Vlam, K, i dr.
Izdano: (2021)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
od: Taylor, PC, i dr.
Izdano: (2020)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
od: Taylor, P, i dr.
Izdano: (2019)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
od: de Vlam, K, i dr.
Izdano: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2018)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
od: Taylor, PC, i dr.
Izdano: (2021)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
od: Taylor, P, i dr.
Izdano: (2022)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Gladman, DD, i dr.
Izdano: (2022)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
od: Coates, L, i dr.
Izdano: (2021)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
od: Dougados, M, i dr.
Izdano: (2020)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
od: Philip J. Mease, i dr.
Izdano: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
od: Peter C. Taylor, i dr.
Izdano: (2022-07-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Dafna D. Gladman, i dr.
Izdano: (2022-02-01)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
od: Iain B McInnes, i dr.
Izdano: (2020-02-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
od: Taylor, P, i dr.
Izdano: (2020)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
od: Laura C. Coates, i dr.
Izdano: (2021-03-01)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
od: Alexis Ogdie, i dr.
Izdano: (2024-09-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
od: Dougados, M, i dr.
Izdano: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
od: Maxime Dougados, i dr.
Izdano: (2022-11-01)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
od: Kristensen, LE, i dr.
Izdano: (2023)

Methotrexate in psoriasis and psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2020)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
od: Nash, P, i dr.
Izdano: (2020)

Psoriatic arthritis
od: FitzGerald, O, i dr.
Izdano: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
od: Marta Skorupska, i dr.
Izdano: (2024-06-01)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
od: Daniela Graham, i dr.
Izdano: (2021-04-01)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
od: Philip J Mease, i dr.
Izdano: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
od: Philip J Mease, i dr.
Izdano: (2019-06-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
od: Kevin L. Winthrop, i dr.
Izdano: (2022-12-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
od: Nash, P, i dr.
Izdano: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
od: Burmester, GR, i dr.
Izdano: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
od: Ly K, i dr.
Izdano: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
od: Nash, P, i dr.
Izdano: (2018)

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire
od: Coates, LC, i dr.
Izdano: (2020)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
od: Gerd R. Burmester, i dr.
Izdano: (2023-07-01)

Patient perception of medical care for psoriatic arthritis in North America and Europe: results from a global patient survey
od: Richette, P, i dr.
Izdano: (2022)

Distinguishing rheumatoid arthritis from psoriatic arthritis
od: Joseph F Merola, i dr.
Izdano: (2018-08-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
od: Peter Nash, i dr.
Izdano: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
od: Leung, Y, i dr.
Izdano: (2018)